A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

Summary

The purpose of the study is to explore the combination of a bivalent vaccine, a sugar called beta-glucan (β-glucan), and a protein called granulocyte-macrophage colony stimulating factor (GM-CSF) as an effective treatment for people with high-risk neuroblastoma that is in complete remission. The combination may be effective because the different parts of the treatment work to strengthen the immune system's response against cancer cells in different ways.

Timeline

Start

2021-08-02

Primary completion

2027-06-15

Completion

2027-06-15

Drugs

Indications